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Volume 58, Number 6 Abstracts 1727P ¼ .001) (Fig 1, A). IPA was used to identify the gene networks and
signaling pathways surrounding p27kip1. Nineteen probes sets within the
microarray were identiﬁed to be components of the p27 network (Table).
Sixteen of these genes encode nuclear proteins, the majority of which are
transcription regulators. The top functions of this gene set are cell cycle
regulation (13 genes), cellular growth and proliferation (17), gene expres-
sion (11), cellular development (14), and cell death and survival (12). A
supervised clustering analysis of these genes revealed two primary patterns of
gene expression, yielding two sets of genes with unique patterns of
expression (Fig 1, B). Cluster A was characterized by a more delayed but
prolonged upregulation compared with cluster B. Additionally, cluster B
exhibits greater upregulation at 7 days, and greater downregulation at 28
days in the high-ﬂow vs the low-ﬂow grafts, suggesting a global ﬂow-
dependent genomic response (Fig 2).
Conclusions: Vein graft remodeling is a complex process driven by
the interplay of local and systemic biology with mechanical forces. Despite
technological advances and improvements in surgical techniques, the precise
factors that determine whether a vein graft adopts an adaptive, outwardly
remodeling phenotype, vs an occlusive phenotype, are largely unknown. A
SNP of the p27kip1 gene, a key cell-cycle regulator, has recently been asso-
ciated with improved revascularization outcomes, yet the mechanisms
underlying this clinical observation remain undeﬁned. Here we attempt to
dissect the gene pathways and networks at play in shaping these divergent
outcomes. In the current analysis, we demonstrate that time-dependent
response to injury following vein graft implantation exerts the dominant
inﬂuence on alterations in the p27kip1 regulatory network. Although
changes in ﬂow result in marked differences in graft phenotype, this biologicTable. p27kip1 associated genes
Gene symbol Entrez gene name
ATG5 autophagy related 5
ATR ataxia telangiectasia and Rad3 related
CDK6 cyclin-dependent kinase 6
COPS5 COP9 signalosome subunit 5
DDB1 damage-speciﬁc DNA binding protein 1
DUSP9 dual speciﬁcity phosphatase 9
HMG20B high mobility group 20B
LHX1 LIM homeobox 1
MED1 mediator complex subunit 1
NCOA6 nuclear receptor coactivator 6
NRIP1 nuclear receptor interacting protein 1
PA2G4 proliferation-associated 2G4, 38kDa
PAK1IP1 PAK1 interacting protein 1
RAN RAN, member RAS oncogene family
RPL5 ribosomal protein L5
RPL23A ribosomal protein L23a
SMAD4 SMAD family member 4
TCF4 transcription factor4
UBE3A ubiquitin protein liqase E3Aimpact is mediated by a broad modulation of the p27kip1 pathway. Differ-
ence in gene expression between high and low ﬂow occurred predominately
in the 1- to 4-week timeframe, the time at which robust proliferation is
dominating the rapid growth of the intima. Intervention of the p27kip1
pathway may offer an important option for modulating cell cycle processes
that contribute to maladaptive vascular remodeling. In particular, cyto-
plasmic ribosomal and autophagy proteins appear to be the most promising
candidates for therapeutic intervention.
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Objectives: Thoracic endovascular aortic repair (TEVAR) is widely
used for treatment of traumatic aortic injury (TAI). Stent graft coverage
of the left subclavian artery (LSA) may be required in up to 40% of cases.
We evaluated the long-term effects of intentional LSA coverage on symp-
toms and return to normal activity in TAI patients, compared with a similarly
treated group without LSA coverage.
Methods: Patients were identiﬁed from a prospective institutional
trauma registry between September 2005 and July 2012. TAI was
conﬁrmed using computed tomographic angiography. The electronic
medical records, angiograms, and computed tomographic angiographies
were reviewed in a retrospective fashion. Personal or telephone interviews
were conducted using the SF-12v2 to assess quality of life. An additional
questionnaire was used to assess speciﬁc LSA symptoms and the ability to
return to normal activities. Data were analyzed by spearman rank correlation
and multiple linear and logistic regression analysis with appropriate transfor-
mations (SAS software).
Results: During the study period, 82 patients (57 male, mean age
49.5 6 20 years, mean ISS 34 6 10.0) underwent TEVAR for treatment
of TAI. Among them, 32 (39.5%) required left subclavian artery coverage
(LSAC), while 50 had their LSA uncovered (LSAU). We found no statisti-
cally signiﬁcant difference in SF-12 physical health scores (r ¼ .08; P ¼
.62) between LSAC and LSAU patients. LSAC patients had slightly better
mental health scores (r ¼ .62; P ¼ .037) than LSAU. LSAC patients did not
have increased likelihood of experiencing pain (r ¼ .0056; P ¼ .97),
numbness (r ¼ .12; P ¼ .45), parasthesia (r ¼ .11; P ¼ .48), fatigue
(r ¼ .066; P ¼ .69), or cramping (r ¼ .12; P ¼ .45). We found no
difference in ability to return to activities between groups. The mean
follow-up time was 3.35 years. Five (16%) of the LSAC patients expired
during the follow-up period due to unrelated causes.
Conclusions: Intentional coverage of the LSA during TEVAR for
TAI appears safe without compromising mental or physical health
outcomes. Furthermore, LSAC does not increase the long-term risk of
upper extremity symptoms or impairment of normal activities.Location Function
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